This study is accepting new patients by invitation only
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
Summary
- Eligibility
- for people ages 1-55 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Aimmune Therapeutics, Inc.
- ID
- NCT03292484
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 950 study participants
- Last Updated